Published in Obesity and Diabetes Week, December 20th, 2004
Under the agreement, Cengent will apply its proprietary platform lead identification technology, Genes To Leads, to screen for drug candidates against diabetic related kidney and heart disease, blindness and neuropathy.
The proprietary drug target of Dynamis Therapeutics, Inc., is an enzyme that causes the formation of 3-deoxyglucosone. 3-deoxyglucosone is an adversely reactive molecule that causes the formation of free radicals and AGEs,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week